Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

entation, subgroup analyses from the SPIRIT III trial demonstrated evidence of the strong performance by XIENCE V in a variety of patients and lesion types that represent complex patients. In patients with diabetes, the analysis showed there was no difference at three years in MACE between XIENCE V and TAXUS (11.0 percent for XIENCE V vs. 10.3 percent in TAXUS)*** . In fact, XIENCE V maintained a consistent rate of clinical events after the first year (8.7 percent MACE at one year and 11.0 percent MACE at three years), whereas TAXUS demonstrated a sustained upward trend in clinical events from one year to three years (4.7 percent MACE at one year and 10.3 percent MACE at three years). In patients without diabetes, the MACE rate for TAXUS at three years was more than double the MACE rate for XIENCE V at three years (9.1 percent for XIENCE V vs. 18.7 percent for TAXUS).

"The SPIRIT III data clearly show that XIENCE V performs in a consistent manner, with clinical benefits continuing to improve over time compared to TAXUS," said Robert Hance, senior vice president, vascular, Abbott. "We are pleased to begin this year's TCT conference with a strong showing of data for Abbott's market-leading XIENCE V, and look forward to presenting the highly anticipated SPIRIT IV one-year results later this week, which should provide physicians with additional valuable insights."

One-year results from the company's SPIRIT IV trial will be presented on Wednesday, Sept. 23, during the first late-breaking clinical trials session of the TCT conference. The SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents, with 3,690 patients enrolled, including more than 1,000 patients with diabetes. The study results will provide valuable information about the efficacy and safety of XIENCE V compared to TAXUS. The SPIRIT III trial was not designed to analyze statistical differences in any of the patient subgroups, as th
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
(Date:5/22/2015)... 2015 The North American dental lasers ... estimated to reach $90.7 million by 2019, at a CAGR ... the TOC of North America Dental Lasers Market for an ... various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... report.   Dental lasers are specifically used ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... June 14 REO, a leading manufacturer ... Mark Notarfrancesco to the newly created position of ... will direct all aspects of the company,s optics fabrication, ... joining REO, Mark served with Intel Corporation developing and ...
... MARLTON, N.J. , June 14 While Father,s Day ... might give your father or spouse is help and support during the difficult ... , , ... needless distress and side effects, says Michael Diefenbach , Ph.D., associate professor ...
Cached Medicine Technology:Mark Notarfrancesco Joins REO as VP Manufacturing Operations 2Prostate Cancer: The Father's Day Gift You Never Thought About 2
(Date:5/26/2015)... Ontario, CA (PRWEB) May 26, 2015 ... hand protection since 1997, is excited to announce the ... the first medical grade gloves made of polyethylene (PE) ... diagnosis, examination and general applications. , The ... used in making sandwiches or mixing salads but our ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 On June ... a complimentary live online broadcast at 6:00pm PST/9:00 pm ... and Trivedi Master™ Alice Branton welcomes the public to ... a night of profound knowledge, transformation and enlightenment. ... Effect® and no previous knowledge, experience or other prerequisites ...
(Date:5/26/2015)... EMIGSVILLE, PA (PRWEB) May 26, 2015 ... oXygen® XML Editor with the Vasont® CCMS to ... process. Vasont Systems, a top component content management ... Universal Integrator (VUI) extension supports oXygen XML Editor ... , The Vasont Universal Integrator extension merges key ...
(Date:5/26/2015)... 26, 2015 General Networks Corporation ... Corporation. The alliance ensures joint customers will benefit ... General Networks’ expertise in building enterprise content and ... will help customers integrate, manage and operationalize their ... processes. , “Our customers are seeking tools to ...
(Date:5/26/2015)... Foot and Ankle Specialists of ... Leone (Pasadena and Baltimore Divisions) was recently presented ... Medical Association (MPMA) President from 2013 to 2015 at ... Doctorate in Podiatric Medicine from Temple University in 1999 ... in Voorhees, New Jersey. Dr. Leone is an ...
Breaking Medicine News(10 mins):Health News:Enov8® Exam Glove by Adenna® Approved by U.S. FDA 2Health News:The Human Wellness Company Trivedi Master Wellness™ Opens a Complimentary Transformational Community Call to the Public on June 4, 2015 2Health News:The Human Wellness Company Trivedi Master Wellness™ Opens a Complimentary Transformational Community Call to the Public on June 4, 2015 3Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2Health News:General Networks Corporation Announces Alliance with MarkLogic 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives MPMA Service Award 2
... , FRIDAY, Sept. 9 (HealthDay News) -- College ... power over time, but smaller improvements in speed and ... physical capabilities of 289 Division III college players throughout ... senior year, the players, body mass increased an average ...
... News) -- More than one-half of all adverse drug ... according to a new study. In addition, prior ... which include drug overdoses and internal bleeding associated with ... are life-threatening, said the Swedish researchers. This widespread problem, ...
... , FRIDAY, Sept. 9 (HealthDay News) -- Fundraising methods such ... the ability to make a donation on state income tax ... and prevention programs in the United States, a new study ... enable taxpayers to check a box on their income tax ...
... Coukell, a pharmacist and director of medical programs at ... Health Education Labor and Pensions Committee about the need ... U.S. drug supply. Nearly 80 percent ... Increasingly, Americans rely on pharmaceuticals that are produced ...
... By Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. ... anxious about caring for their infant. But sometimes that concern ... go wrong. Experts call that condition postpartum obsessive compulsive ... prevent their fears from coming true, such as endlessly washing ...
... (HealthDay News) -- People are at much higher risk ... according to a new study. Canadian researchers found ... is likely to develop COPD, which they called "one of ... emphysema and chronic bronchitis, and the overall risk for developing ...
Cached Medicine News:Health News:Over Half of Adverse Drug Reactions in Hospitals Are Preventable: Study 2Health News:When Protecting Baby Becomes an Obsession 2Health News:When Protecting Baby Becomes an Obsession 3Health News:Risk for COPD Higher Than Thought: Study 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: